Barinthus Biotherapeutics plc (FRA:2AB)
Germany · Delayed Price · Currency is EUR 0.6400
+0.0050 (0.79%)
At close: Nov 28, 2025
Barinthus Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| - | 14.97 | 0.8 | 44.7 | 0.27 | 4.82 | Upgrade | |
Revenue Growth (YoY) | - | 1766.46% | -98.21% | 16580.22% | -94.44% | -29.57% | Upgrade |
Cost of Revenue | -10.52 | 1.68 | 2.01 | 42.35 | 20.37 | 14.39 | Upgrade |
Gross Profit | 10.52 | 13.29 | -1.21 | 2.35 | -20.1 | -9.57 | Upgrade |
Selling, General & Admin | 30.04 | 23.54 | 39.79 | 6.47 | 25.12 | 10.48 | Upgrade |
Research & Development | 36.58 | 36.57 | 39.4 | -1.24 | -4 | -3.28 | Upgrade |
Other Operating Expenses | -1.25 | -1.18 | - | - | - | - | Upgrade |
Operating Expenses | 65.38 | 58.94 | 79.19 | 5.23 | 21.12 | 7.2 | Upgrade |
Operating Income | -54.86 | -45.65 | -80.4 | -2.87 | -41.22 | -16.77 | Upgrade |
Interest Expense | -0.05 | -0.05 | -0.03 | -0.02 | -2.67 | -3.6 | Upgrade |
Interest & Investment Income | 2.19 | 2.68 | 2.88 | 3.1 | 0 | - | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | - | 0.21 | 0.45 | Upgrade |
Other Non Operating Income (Expenses) | 0.21 | 0.14 | 1.08 | 0.57 | 6.33 | 2.08 | Upgrade |
EBT Excluding Unusual Items | -52.52 | -42.89 | -76.47 | 0.78 | -37.35 | -17.84 | Upgrade |
Impairment of Goodwill | -12.21 | -12.21 | - | - | - | - | Upgrade |
Asset Writedown | -9.93 | -5.26 | - | - | - | - | Upgrade |
Other Unusual Items | -1.41 | -0.87 | -0.06 | 0.07 | -13.79 | - | Upgrade |
Pretax Income | -76.06 | -61.23 | -76.52 | 0.85 | -51.14 | -17.84 | Upgrade |
Income Tax Expense | -0.12 | -0.04 | -3.08 | -4.47 | -0.03 | 0.1 | Upgrade |
Earnings From Continuing Operations | -75.95 | -61.18 | -73.45 | 5.32 | -51.11 | -17.93 | Upgrade |
Minority Interest in Earnings | 0.07 | 0.11 | 0.1 | 0.02 | 0.25 | 0.23 | Upgrade |
Net Income | -75.88 | -61.07 | -73.35 | 5.34 | -50.87 | -17.71 | Upgrade |
Net Income to Common | -75.88 | -61.07 | -73.35 | 5.34 | -50.87 | -17.71 | Upgrade |
Shares Outstanding (Basic) | 40 | 39 | 38 | 37 | 26 | 8 | Upgrade |
Shares Outstanding (Diluted) | 40 | 39 | 38 | 38 | 26 | 8 | Upgrade |
Shares Change (YoY) | 3.60% | 2.50% | 0.57% | 47.40% | 227.59% | 33580.72% | Upgrade |
EPS (Basic) | -1.88 | -1.55 | -1.91 | 0.14 | -1.96 | -2.24 | Upgrade |
EPS (Diluted) | -1.88 | -1.55 | -1.91 | 0.14 | -1.96 | -2.24 | Upgrade |
Free Cash Flow | -30.97 | -29.83 | -56.34 | -20.57 | -33.73 | -11.32 | Upgrade |
Free Cash Flow Per Share | -0.77 | -0.76 | -1.47 | -0.54 | -1.30 | -1.43 | Upgrade |
Gross Margin | - | 88.78% | -150.75% | 5.26% | - | -198.42% | Upgrade |
Operating Margin | - | -304.98% | -10024.69% | -6.43% | -15380.60% | -347.79% | Upgrade |
Profit Margin | - | -408.00% | -9145.51% | 11.95% | -18979.48% | -367.27% | Upgrade |
Free Cash Flow Margin | - | -199.29% | -7024.69% | -46.01% | -12585.45% | -234.83% | Upgrade |
EBITDA | -51.7 | -43.05 | -78.17 | -1.75 | -40.82 | -16.56 | Upgrade |
EBITDA Margin | - | -287.61% | - | -3.92% | - | - | Upgrade |
D&A For EBITDA | 3.16 | 2.6 | 2.23 | 1.12 | 0.4 | 0.21 | Upgrade |
EBIT | -54.86 | -45.65 | -80.4 | -2.87 | -41.22 | -16.77 | Upgrade |
EBIT Margin | - | - | - | -6.43% | - | - | Upgrade |
Revenue as Reported | - | 14.97 | 0.8 | 44.7 | 0.27 | 4.82 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.